A comprehensive clinical guide to Acute Myocardial Infarction (AMI). Explore the latest protocols for STEMI and NSTEMI, high-sensitivity troponin assays, and evidence-based reperfusion therapies for healthcare professionals.
 |
| Acute Myocardial Infarction (MI) |
Acute Myocardial Infarction (AMI)
Symptoms: Typically moderate-to-severe chest discomfort lasting over 20 minutes. Atypical presentations are more frequent in women, the elderly, and patients with diabetes.
Diagnosis: Relies on the Electrocardiogram (ECG) and cardiac biomarkers (Troponin and CK-MB).
Classification:
STEMI: ST-segment elevation on ECG, indicating complete arterial occlusion.
NSTE-ACS: Non-ST elevation, further stratified into NSTEMI (elevated biomarkers) or Unstable Angina (no biomarker elevation).
"TIME IS MUSCLE": Management is centered on reestablishing blood flow as fast as possible to prevent myocyte death.
Hospital Care & Discharge Checklist (The ABCDE List)
To reduce the risk of recurrent MI or death, the "ABCDE" guide is used for inpatient treatment and discharge:
A (Antiplatelet/Anticoagulation): Aspirin (indefinitely), Clopidogrel/Prasugrel (at least 1 year), Heparin during hospital stay, and ACE-Inhibitors for low EF or hypertension.
B (Beta-blocker & Blood Pressure): Beta-blockers for all (unless contraindicated); BP goal < 140/90 (or < 130/80 for diabetes/kidney disease).
C (Cigarette Cessation & Cholesterol): Complete smoking cessation and high-dose Statin therapy (Goal LDL < 70 mg/dL).
D (Diet & Diabetes): Weight reduction if BMI > 25 and tight glucose control (Goal Hgb A1c < 7.0%).
E (Exercise & Ejection Fraction): 30 minutes of aerobic activity 5 days/week and measurement of EF prior to discharge.
Management of STEMI (The "3D's" Flow)
The management of a STEMI patient follows a strict timeline. It begins with the Patient Goal of calling EMS within 5 minutes of symptom onset. Transport goals require EMS on the scene within 8 minutes. Upon arrival at a Medical Facility, the "3Ds" are triggered: DATA (ECG within 10 minutes), DECISION and DRUG
The primary Decision is between Primary PCI (preferred, with a medical contact-to-balloon goal of \le 90 minutes) and Fibrinolytic Therapy (if PCI is unavailable, with a contact-to-needle goal of \le 30 minutes). Fibrinolytics are avoided if there is a history of hemorrhagic stroke or active bleeding. All patients receive a suite of Drugs including Aspirin (162–325 mg), Metoprolol, Nitroglycerin, and anticoagulants like Heparin or Enoxaparin. If fibrinolysis is successful (noted by 50% ST-segment improvement), the patient is monitored; if it fails, they are moved to "Rescue PCI." Risk-Stratification for NSTE-ACS
For patients without ST-elevation, the process starts with an Evaluation of the 3Ds. Patients are triaged into High, Intermediate, or Low Likelihood of ACS based on pain duration, heart failure signs, and ECG changes (like ST depression > 0.5 mm). If ACS is "Definite or Likely," the patient is started on Aspirin, Nitrates, and Anticoagulants.
The clinician then uses the TIMI Risk Score (0–7 points) to Select a Management Strategy. A high TIMI score (5–7) or clinical triggers like recurrent pain, hemodynamic instability, or low EF favors an Invasive Strategy (diagnostic catheterization within 48 hours). A low risk score (0–2) or patient preference favors a Conservative Strategy, which involves a noninvasive stress test. If the stress test is "not low risk" or EF is < 40%, the patient is moved back to the invasive catheterization pathway.
Management of Type 2 MI
Unlike Type 1 MI (plaque rupture),
Type 2 MI is caused by an oxygen supply-demand mismatch (e.g., due to tachycardia, anemia, or respiratory failure)
Focus on the Data (history, ECG, and Echo to check for wall motion abnormalities). The critical Decision is to treat and correct the underlying cause of the oxygen mismatch. After the acute stressor is resolved, patients undergo a Noninvasive Cardiac Stress Test. If the test shows a high risk, they proceed to diagnostic catheterization; if low risk, the focus shifts to aggressive risk factor modification for primary prevention.
classification of Myocardial Infarction (MI) is divided into five distinct types based on the underlying clinical cause.
Type 1 MI is the "classic" spontaneous event resulting from a primary coronary issue, such as plaque rupture, ulceration, or erosion that leads to a blood clot.
Type 2 MI occurs not because of plaque instability, but due to a mismatch between myocardial oxygen supply and demand; this is often triggered by external stressors like severe anemia, respiratory failure, or extreme hypertension.
Type 3 MI is reserved for cases of sudden cardiac death where symptoms suggest a heart attack occurred, but the patient passes away before cardiac biomarkers (like troponin) can be measured or show an elevation.
Type 4 is related to interventional procedures and is split into two subcategories:
Type 4a is an MI associated specifically with Percutaneous Coronary Intervention (PCI), requiring biomarkers to reach more than three times the upper limit of normal, while
Type 4b is caused by the documented formation of a clot within a stent (stent thrombosis). Finally, Type 5 MI is associated with Coronary Artery Bypass Grafting (CABG) surgery, where biomarkers must exceed five times the upper limit of normal to confirm the diagnosis.